The Gap Junction Beta 2 Protein pipeline drugs market research report outlays comprehensive information on the Gap Junction Beta 2 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Gap Junction Beta 2 Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ear Nose Throat Disorders which include the indications Hearing Disorders, and Deafness. It also reviews key players involved in Gap Junction Beta 2 Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Gap Junction Beta 2 Protein pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Gap Junction Beta 2 Protein overview
Gap Junction Beta 2 Protein (GJB2), also known as connexin 26, is a member of the connexin family of proteins that form gap junctions, allowing direct cell-to-cell communication. GJB2 is widely expressed in various tissues, with a prominent presence in the inner ear, skin, and other epithelial tissues. Its crucial role lies in facilitating the exchange of ions, small molecules, and signaling molecules between adjacent cells. In the auditory system, GJB2 is particularly important for normal hearing function. Mutations in the GJB2 gene are a leading cause of non-syndromic hearing loss, a condition characterized by hearing impairment without other associated medical issues. The loss of functional GJB2 disrupts the normal flow of ions in the inner ear, affecting the proper function of sensory hair cells and leading to hearing deficits. GJB2’s significance extends beyond the auditory system. It plays a role in the regulation of cell growth, differentiation, and tissue homeostasis. Additionally, mutations in GJB2 have been implicated in various skin disorders, highlighting its importance in the maintenance of skin integrity.
For a complete picture of Gap Junction Beta 2 Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
